Topic: tax reform

Pharma companies Pfizer, Merck and Johnson & Johnson are dodging billions of dollars of tax payments annually, an Oxfam report concluded.

AbbVie donated $100 million to Ronald McDonald House Charities this week, part of its ongoing 2018 tax-windfall handout of $350 million to charities.

AbbVie has stored dozens of Humira patents in Bermuda, allowing it to lower its corporate tax rate, according to Reuters.

Pharma authorized tens of billions of dollars' worth of share buybacks before or shortly after tax reform, and that irked an industry veteran.

Takeda hasn’t even approached Shire’s board with a buyout offer yet, but competing bidders could jump in quickly, thanks to U.K. takeover rules.

Pfizer’s board of directors is providing rich incentives to keep CEO Ian Read on board as the company navigates a host of challenges.

Some drugmakers reap far more savings from tax reform than others—and some will actually have to pay more. Here's our report card.

Merck is projecting a flat tax rate this year as many of its peers expect to see a benefit.

Several pharma companies have thrilled investors with their sunny predictions—but not Amgen.